FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551331192> ?p ?o ?g. }

• W2551331192 endingPage "5190" @default.
• W2551331192 startingPage "5190" @default.
• W2551331192 abstract "Abstract BACKGROUND Myeloproliferative neoplasms (MPN) are a group of clonal disorders that arise from a transformation in a hematopoietic stem cell. These disorders consist of chronic myeloid leukemia (CML), essential thrombocytosis (ET), primary myelofibrosis (PMF) and polycythemia vera (PCV). Several therapeutic agents have been used in the past to treat these disorders. Treatment strategies for these patients must consider the possibility of long-term survival, morbidity from thrombotic complications, transformation into myelofibrosis with myeloid metaplasia or acute myeloid leukemia, and the effect of specific therapies on the incidence of leukemic transformation and on pregnancy. At Drexel University, a significant number of patients were treated with busulfan and were thought to have a more favorable clinical course and increased survival in comparison to other agents. Due to the perceived side effects associated with busulfan, the current preferred cytoreductive agent is hydroxyurea. In our study we analyzed the outcomes of patients treated in the practice of I. Brodsky Associates diagnosed with ET, PCV and PMF, who received a variety of treatment modalities, and compared their clinical courses to determine if there is a superior treatment. METHODS This study is a retrospective cohort study in which we have examined the medical records of patients treated for the diagnoses of ET, PCV and PMF at Hahnemann Hospital-Drexel University College Medicine in the practice of I. Brodsky Associates from January 1960 to December 2013. The following variables were measured and compared: age at diagnosis; sex; race; cytogenetics; family history of malignancy; baseline hemoglobin, hematocrit, platelet count and WBC count; Bone marrow biopsy results; thrombohemorrhagic complications; transformation to acute leukemia, progression to myelofibrosis; development of secondary malignancies; and treatment. Since the diagnostic criteria for myeloproliferative disorders has evolved over the years, information regarding JAK2 V617F mutation status, initial erythropoietin level, red cell mass, oxygen saturation, presence of splenomegaly and B12 level were also collected in order to confirm the diagnosis of each patient. The treatment categories analyzed were: Busulfan Only, Hydroxyurea Only, Aspirin with or without Plavix only, Both Busulfan and Hydroxyurea, and Phlebotomy Alone. The forms were then analyzed using Prism software and the number of observations, percentages, means, standard deviation, and minimum and maximum values were obtained for all measurements. Survival was calculated using Kaplan-Meier analysis. RESULTS 119 patients with a MPN were identified: 47 ET, 56 PCV, 8 PMF and 7 MPN NOS. Median ages were 70, 75, 63 and 67, respectively. 34 received Busulfan, 26 Hydroxyurea, 24 Busulfan and hydroxyurea, 24 Aspirin/Plavix only, 11 phlebotomy; one patient who was given Interferon and Aspirin was excluded from analysis. Table. Median survival based on treatment regimen in months: Aspirin/Plavix Busulfan+Hydroxyurea Hydroxyurea Busulfan Phlebotomy 119 178 98 173 145 Table. Number of patients with complications associated with toxicities based on treatment regimens: Complication Aspirin/ Plavix Busulfan+ Hydroxyurea Hydroxyurea Busulfan Phlebotomy Thromboses 9 14 5 9 4 Hemorrhage 3 2 2 6 0 Leukemic transformation 0 1 5 2 0 Malignancy 0 5 1 5 0 Malignancies noted: Pancreatic cancer (4), Breast cancer (4), and Non-Hodgkin's lymphoma (3). Basal and squamous cell skin cancers were excluded. CONCLUSIONS MPN have been treated in much the same way for many years although few physicians use busulfan as routinely as I. Brodsky Associates. Our study set out to discover if this uncommon treatment correlated with improved survival and less treatment toxicity. Busulfan and hydroxyurea given together proved to have the lowest rate of progression to leukemia or myelofibrosis when compared to other standard therapies. The median survival of patients treated with both busulfan and hydroxyurea was 14.8 years. More patients on busulfan developed solid tumors, which could be possibly due to their longer survival rates, but increased leukemic transformation was not observed. In conclusion, patients treated with hydroxyurea and intermittent busulfan, were shown to have the best long-term outcomes. This suggests that physicians should consider using busulfan to treat MPNs. Disclosures No relevant conflicts of interest to declare." @default.
• W2551331192 created "2016-11-30" @default.
• W2551331192 creator A5011800075 @default.
• W2551331192 creator A5014181199 @default.
• W2551331192 creator A5026289935 @default.
• W2551331192 creator A5027903860 @default.
• W2551331192 creator A5043798234 @default.
• W2551331192 creator A5052147753 @default.
• W2551331192 creator A5077052409 @default.
• W2551331192 creator A5090154787 @default.
• W2551331192 date "2015-12-03" @default.
• W2551331192 modified "2023-09-27" @default.
• W2551331192 title "A Retrospective Analysis of Myeloproliferative Neoplasms: Treatment Approach and Outcomes at Drexel University Hospital" @default.
• W2551331192 doi "https://doi.org/10.1182/blood.v126.23.5190.5190" @default.
• W2551331192 hasPublicationYear "2015" @default.
• W2551331192 type Work @default.
• W2551331192 sameAs 2551331192 @default.
• W2551331192 citedByCount "0" @default.
• W2551331192 crossrefType "journal-article" @default.
• W2551331192 hasAuthorship W2551331192A5011800075 @default.
• W2551331192 hasAuthorship W2551331192A5014181199 @default.
• W2551331192 hasAuthorship W2551331192A5026289935 @default.
• W2551331192 hasAuthorship W2551331192A5027903860 @default.
• W2551331192 hasAuthorship W2551331192A5043798234 @default.
• W2551331192 hasAuthorship W2551331192A5052147753 @default.
• W2551331192 hasAuthorship W2551331192A5077052409 @default.
• W2551331192 hasAuthorship W2551331192A5090154787 @default.
• W2551331192 hasConcept C126322002 @default.
• W2551331192 hasConcept C143998085 @default.
• W2551331192 hasConcept C167135981 @default.
• W2551331192 hasConcept C187212893 @default.
• W2551331192 hasConcept C2777408962 @default.
• W2551331192 hasConcept C2778837598 @default.
• W2551331192 hasConcept C2780007613 @default.
• W2551331192 hasConcept C2780076729 @default.
• W2551331192 hasConcept C2780611847 @default.
• W2551331192 hasConcept C2780829020 @default.
• W2551331192 hasConcept C2781057849 @default.
• W2551331192 hasConcept C2911091166 @default.
• W2551331192 hasConcept C71924100 @default.
• W2551331192 hasConceptScore W2551331192C126322002 @default.
• W2551331192 hasConceptScore W2551331192C143998085 @default.
• W2551331192 hasConceptScore W2551331192C167135981 @default.
• W2551331192 hasConceptScore W2551331192C187212893 @default.
• W2551331192 hasConceptScore W2551331192C2777408962 @default.
• W2551331192 hasConceptScore W2551331192C2778837598 @default.
• W2551331192 hasConceptScore W2551331192C2780007613 @default.
• W2551331192 hasConceptScore W2551331192C2780076729 @default.
• W2551331192 hasConceptScore W2551331192C2780611847 @default.
• W2551331192 hasConceptScore W2551331192C2780829020 @default.
• W2551331192 hasConceptScore W2551331192C2781057849 @default.
• W2551331192 hasConceptScore W2551331192C2911091166 @default.
• W2551331192 hasConceptScore W2551331192C71924100 @default.
• W2551331192 hasIssue "23" @default.
• W2551331192 hasLocation W25513311921 @default.
• W2551331192 hasOpenAccess W2551331192 @default.
• W2551331192 hasPrimaryLocation W25513311921 @default.
• W2551331192 hasRelatedWork W1990387953 @default.
• W2551331192 hasRelatedWork W2011253478 @default.
• W2551331192 hasRelatedWork W2088772354 @default.
• W2551331192 hasRelatedWork W2143777695 @default.
• W2551331192 hasRelatedWork W2318732531 @default.
• W2551331192 hasRelatedWork W2324926716 @default.
• W2551331192 hasRelatedWork W2531810619 @default.
• W2551331192 hasRelatedWork W2547696146 @default.
• W2551331192 hasRelatedWork W2551331192 @default.
• W2551331192 hasRelatedWork W2571034276 @default.
• W2551331192 hasVolume "126" @default.
• W2551331192 isParatext "false" @default.
• W2551331192 isRetracted "false" @default.
• W2551331192 magId "2551331192" @default.
• W2551331192 workType "article" @default.